Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EYPT 
Eyepoint Pharmaceuticals Inc (EYPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: EYPT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 91.47% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 347.08M USD | Price to earnings Ratio - | 1Y Target Price 33 |
Price to earnings Ratio - | 1Y Target Price 33 | ||
Volume (30-day avg) 770808 | Beta 1.42 | 52 Weeks Range 5.00 - 23.64 | Updated Date 04/1/2025 |
52 Weeks Range 5.00 - 23.64 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.4765 | Actual -0.64 |
Profitability
Profit Margin - | Operating Margin (TTM) -390.4% |
Management Effectiveness
Return on Assets (TTM) -23.57% | Return on Equity (TTM) -43.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23454879 | Price to Sales(TTM) 8.02 |
Enterprise Value 23454879 | Price to Sales(TTM) 8.02 | ||
Enterprise Value to Revenue 0.54 | Enterprise Value to EBITDA -11.49 | Shares Outstanding 68728800 | Shares Floating 43542419 |
Shares Outstanding 68728800 | Shares Floating 43542419 | ||
Percent Insiders 1.16 | Percent Institutions 109.63 |
Analyst Ratings
Rating 4.67 | Target Price 33.42 | Buy 4 | Strong Buy 8 |
Buy 4 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Eyepoint Pharmaceuticals Inc
Company Overview
History and Background
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) was founded in 1987. It focuses on developing and commercializing innovative ophthalmic products.
Core Business Areas
- Drug Delivery Systems: Developing and commercializing sustained-release drug delivery systems for treating eye diseases.
- Ophthalmology Products: Focusing on treatments for retinal diseases like diabetic macular edema (DME), wet age-related macular degeneration (wet AMD) and glaucoma.
Leadership and Structure
Nancy Lurker is the Chief Executive Officer. The company has a board of directors and operates with functional teams for R&D, commercialization, and operations.
Top Products and Market Share
Key Offerings
- YUTIQ: A sustained-release intravitreal micro-insert containing fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Competitors include corticosteroids and other anti-inflammatory therapies. Market share is growing but specific numbers are not public.
- Durasert: A sustained-release drug delivery technology platform used in YUTIQ and other products. Competitors are other long acting drug delivery technologies.
- Lexiscan: A pharmacologic stress agent used in myocardial perfusion imaging. Lexiscan generated revenues of $36.4 million in 2023. Competitors are Adenosine and Dobutamine.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is growing due to the aging population and increasing prevalence of eye diseases like glaucoma and macular degeneration. There is a growing demand for sustained-release drug delivery systems.
Positioning
EyePoint Pharmaceuticals is positioned as an innovator in sustained-release ophthalmic drug delivery. Its competitive advantage lies in its proprietary Durasert technology and focus on retinal diseases.
Total Addressable Market (TAM)
The global ophthalmic drugs market is estimated to reach $45.3 billion by 2029. EyePoint Pharmaceuticals is positioned to capture a share of this market with its innovative products and drug delivery technologies.
Upturn SWOT Analysis
Strengths
- Proprietary Durasert technology
- FDA-approved products (YUTIQ)
- Experienced management team
- Focus on high-growth ophthalmic market segments
Weaknesses
- Reliance on key products for revenue
- Limited commercial infrastructure compared to larger pharmaceutical companies
- Dependence on partnerships for development and commercialization
- History of net losses
Opportunities
- Expanding indications for existing products
- Developing new ophthalmic drug delivery systems
- Acquiring or licensing new ophthalmic products
- Geographic expansion into international markets
Threats
- Competition from larger pharmaceutical companies
- Generic erosion of key products
- Regulatory challenges and delays
- Patent expirations
Competitors and Market Share
Key Competitors
- ALKS
- AGN
- SNY
Competitive Landscape
EyePoint's advantages include its proprietary Durasert technology and focus on sustained-release drug delivery. Disadvantages include its smaller size and limited commercial infrastructure compared to larger competitors.
Major Acquisitions
Equinox Sciences
- Year: 2024
- Acquisition Price (USD millions): 40
- Strategic Rationale: The strategic rationale behind the acquisition was to strengthen and broaden the product portfolio and drug delivery capabilities of EyePoint.
Growth Trajectory and Initiatives
Historical Growth: EyePoint has experienced revenue growth in recent years, driven by sales of YUTIQ and Lexiscan.
Future Projections: Analysts project continued revenue growth for EyePoint, driven by increased adoption of its products and expansion into new markets. The company is expected to achieve profitability in the coming years.
Recent Initiatives: EyePoint is focused on expanding the indications for YUTIQ and developing new ophthalmic drug delivery systems. The company is also exploring strategic partnerships and acquisitions.
Summary
EyePoint Pharmaceuticals is a company with innovative drug delivery technology and a focus on ophthalmic diseases. While the company has shown revenue growth and is focused on strategic initiatives like acquisitions, it faces challenges related to competition, financial stability, and dependence on key products. Future growth will depend on successful commercialization, expansion of existing products, and strategic partnerships. These opportunities will likely bring future growth in revenue for the company.
Similar Companies
- ALKS
- AGN
- SNY
- VRTX
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change. Information obtained from third-party sources and while believed to be accurate, has not been independently verified. Investors should consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eyepoint Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2005-01-27 | President, CEO & Director Dr. Jay S. Duker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 165 | Website https://eyepointpharma.com |
Full time employees 165 | Website https://eyepointpharma.com | ||
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.